Correlation between Therapeutic Drug Monitoring of Infliximab Serum Trough Levels and other Biomarkers in Iraqi Patients with Crohn's Disease

Authors

  • Hussein Hazim Saleh Ghazi Al-Hariri Hospital for Specialized Surgeries, Medical City, Baghdad, Iraq https://orcid.org/0009-0008-0505-1284
  • Dheyaa Jabbar Khadim Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq
  • Raghad Jawad Hussein Gastroenterology and Hepatology Teaching Hospital, Medical City, Baghdad, Iraq

DOI:

https://doi.org/10.54133/ajms.v6i1.606

Keywords:

Antidrug Antibodies, Crohn's Disease, Inflammatory Bowel Disease, Infliximab, Iraqi patients, Therapeutic drug monitoring

Abstract

Background: Inflammatory bowel disease (IBD) is a collection of chronic, recurrent inflammatory illnesses of the gastrointestinal system, including Crohn's disease (CD). Infliximab is one of the biological medications used to treat CD. Therapeutic drug monitoring has evolved as a treatment in IBD, aiming to optimize benefit while meeting more demanding, objective end criteria. Objective: To determine the achievement of target trough level (TL), develop anti-drug antibodies (ADAs) to infliximab, assess response to therapy, and study TL relations with different variables. Methods: The present study was cross-sectional and conducted from May 2022 to November 2022. It included 40 CD patients allotted into 2 groups: group 1 patients achieved the TL target, and group 2 patients did not achieve the TL target. Results: Twenty-two patients achieved target TL, while 18 patients did not. Dose escalation is recommended for 11 patients, switching therapy for 15 patients, and continuing the same dosage regimen for 14 patients. In addition, erythrocyte sedimentation rate, C-reactive protein, serum calprotectin and ADAs were significantly lower in patients who achieved target infliximab TL. Only serum calprotectin can be used to predict the achievement of the target TL of infliximab. Conclusions: Therapeutic drug monitoring of infliximab to determine the TL and ADAs can help to explain why some patients do not respond to this drug. Serum calprotectin may be used as a novel marker to predict the TL and response to infliximab.

Downloads

Download data is not yet available.

References

Alraeai H, Hasan HK, Abdulameer ZA, Hamad QY. Assessment of depression among IBD patients in Gastroenterology and Hepatology Specialized Hospital, Medical City, Iraq using the PHQ-9. J Fac Med Baghdad. 2024;65(4):249-253 doi: 10.32007/jfacmedbagdad.2071.

Jebur N, Kadhim D, Alkhalidi N. Belief about medications among sample of Iraqi patients with inflammatory bowel disease. Iraqi J Pharm Sci. 2018;27:32-41 doi: 10.31351/vol27iss2pp32-41.

Hussian S, Sabri W. Association of inflammatory bowel disease and tumor necrosis factor-863 C/A Polymorphism in Iraq. Int J Drug Del Technol. 2023;13:81-85. doi: 10.25258/ijddt.13.1.12.

Alabassi H, Falih M, Ad'hiah A, Mushe'al K, Mubarak I, Alqaisy I, et al. Serum profile of cytokines in Iraqi inflammatory bowel disease patients. Mustansiriyah Med J. 2021;14:11-16. doi: 10.4103/2070-1128.247848.

Abbas ZK, Zaidan TF. The study of oral findings, oxidative stress and antioxidant vitamin E in serum and saliva of Crohn's patients on azathioprine monotherapy and those on combination of anti-TNF-α plus azathioprine. J Baghdad Coll Dent. 2018;30(1):39-45. doi: 10.12816/0046310.

Kellermann L, Riis LB. A close view on histopathological changes in inflammatory bowel disease, a narrative review. Digest Med Res. 2021;4. doi: 10.21037/dmr-21-1.

Ad’hiah AH, Hessan EB, Shahab BA. Interleukin-1 single nucleotide polymorphisms as risk factors for susceptibility of inflammatory bowel disease: an Iraqi Arab population-based study. Alexandria J Med. 2019;55(1):1-6. doi: 10.1080/20905068.2019.1592938.

Vultaggio A, Matucci A, Nencini F, Pratesi S, Maggi E. Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. Intern Emergency Med. 2012;7(2):77-79. doi: 10.1007/s11739-011-0611-x.

Fadhil H, Al-Jumaili AA, Al-Ani N. Cost-effectiveness analysis of reference infliximab (Remicade) compared to its biosimilar (Remsima) in Iraqi patients with rheumatoid arthritis. Iraqi J Pharm Sci. 2023;31:100-110. doi: 10.31351/vol31issSuppl.pp100-110.

Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis. Aliment Pharmacol Ther. 2018;47(4):478-484. doi: 10.1111/apt.14458.

Casteele NV, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 2015;64(10):1539-1545. doi: 10.1136/gutjnl-2014-307883.

Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn’s disease. Gastroenterol Hepatol (N Y). 2012 Feb;8(2):131-134. PMID: 22485082.

Oh EH, Ko DH, Seo H, Chang K, Kim GU, Song EM, et al. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease. World J Gastroenterol. 2017;23(8):1489-1496. doi: 10.3748/wjg.v23.i8.1489.

Younus MM, Taher MA, Askar BA, Kurmanji JM. Serum selenium correlations with C- reactive protein, calprotectin and disease activity ‎in IBD patients treated with Infliximab. World J Pharmacy Pharm Sci. 2015;4:165-179‎.

Sobolewska A, Włodarczyk M, Stec-Michalska K, Fichna J, Wiśniewska-Jarosińska M. Mean platelet volume in Crohn's disease patients predicts sustained response to a 52-week infliximab therapy: A pilot study. Dig Dis Sci. 2016;61(2):542-9. doi: 10.1007/s10620-015-3894-3.

Bertani L, Barberio B, Fornili M, Antonioli L, Zanzi F, Casadei C, et al. Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab. Dig Liver Dis. 2022;54(10):1367-1373. doi: 10.1016/j.dld.2022.03.008.

Minar P, Lehn CN, Tsai YT, Jackson K, Denson T. Elevation of plasma oncostatin-M is associated with primary and secondary nonresponse to infliximab in pediatric Crohn’s disease patients. Inflamm Bowel Dis. 2019;25(Supplement 1):S54. doi: 10.1093/ibd/izy393.118.

Dotan I, Ron Y, Yanai H, Becker S, Fishman S, Yahav L, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20(12):2247-2259. doi: 10.1097/mib.0000000000000212.

Danese S, Fiorino G, Reinisch W. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy. Aliment Pharmacol Ther. 2011;34(1):1-10. doi: 10.1111/j.1365-2036.2011.04679.x.

Irving PM, Gecse KB. Optimizing therapies using therapeutic drug monitoring: Current strategies and future perspectives. Gastroenterology. 2022;162(5):1512-1524. doi: 10.1053/j.gastro.2022.02.014.

Albader F, Golovics PA, Gonczi L, Bessissow T, Afif W, Lakatos PL. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. World J Gastroenterol. 2021;27(37):6231-6247. doi: 10.3748/wjg.v27.i37.6231.

Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of non-response and loss of response to anti-tumor necrosis factor therapy in inflammatory bowel disease. Front Med. 2022;9. doi: 10.3389/fmed.2022.897936.

Pouillon L, Ferrante M, Van Assche G, Rutgeerts P, Noman M, Sabino J, et al. Mucosal healing and long-term outcomes of patients with inflammatory bowel diseases receiving clinic-based vs trough concentration-based dosing of infliximab. Clin Gastroenterol Hepatol. 2018;16(8):1276-1283. doi: 10.1016/j.cgh.2017.11.046.

Shmais M, Regueiro M, Hashash JG. Proactive versus reactive therapeutic drug monitoring: Why, when, and how? Inflamm Intest Dis. 2021;7(1):50-58. doi: 10.1159/000518755.

Franco DL, Click B. Proactive versus reactive therapeutic drug monitoring of infliximab in Crohn’s disease: Is the juice worth the squeeze? Inflamm Bowel Dis. 2019;26(1):112-113. doi: 10.1093/ibd/izz114.

Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO Guidelines on therapeutics in ulcerative colitis: Medical treatment. J Crohn's Colitis. 2022;16(1):2-17. doi: 10.1093/ecco-jcc/jjab178.

Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in Crohn's disease: Medical treatment. J Crohn's Colitis. 2020;14(1):4-22 doi: 10.1093/ecco-jcc/jjz180.

Peyrin-Biroulet L, Panes J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, et al. Defining disease severity in inflammatory bowel diseases: Current and future directions. Clin Gastroenterol Hepatol. 2016;14(3):348-354. doi: 10.1016/j.cgh.2015.06.001.

Chen M, Shen B. Overview of diagnosis and medical treatment of inflammatory bowel diseases. In: Shen B, (Ed.), Interventional Inflammatory Bowel Disease: Endoscopic Management and Treatment of Complications, Academic Press; 2018. p. 1-15.

Firestein GS, Budd RC, Gabriel SE, McInnes IB, O’Dell JR, (Eds.), Acute Phase Reactants and the Concept of Inflammation, In: Kelley's Textbook of Rheumatology, (9th ed.), Philadelphia, PA: Elsevier Saunders; 2013. p. 818-29.

Shikari® (Q-REMS) Infliximab biosimilar ELISA INF-FD-REMS. Turkey: Matriks Biotek; 2023 [updated Jul 2023; cited 5/8/2023]. Available from: https://matriksbiotek.com/products/132/shikari-q-rems-infliximab-biosimilar-elisa

Shikari® (S-AIR) Anti-Infliximab biosimilar ELISA w/confirmation INF-QNS-REMS. Turkey: Matriks Biotek; 2023 [updated Jul 2023; cited 5/8/2023]. Available from: https://matriksbiotek.com/products/138/shikari-s-air-anti-infliximab-biosimilar-elisa-w-confirmation

Human OSM (Oncostatin M) ELISA Kit (Catalog No: E-EL-H2247). China: Elabscience Biotechnology; 2023 [updated Apr 2023; cited 5/8/2023]. Available from: https://www.elabscience.com/p-human_osm_oncostatin_m_elisa_kit-19660.html

Human CALP (Calprotectin) ELISA Kit (Catalog No: E-EL-H2357). China: Elabscience Biotechnology; 2023 [updated Apr 2023; cited 5/8/2023]. Available from: https://www.elabscience.com/p-human_calp_calprotectin_elisa_kit-19752.html

Sánchez-Hernández JG, Rebollo N, Martin-Suarez A, Calvo MV, Muñoz F. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease. Br J Clin Pharmacol. 2020;86(6):1165-1175. doi: 10.1111/bcp.14229.

Orfanoudaki E, Gazouli M, Foteinogiannopoulou K, Theodoraki E, Legaki E, Romanos I, et al. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab. Eur J Gastroenterol Hepatol. 2019;31(2):187-191. doi: 10.1097/meg.0000000000001332.

Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Sato N, et al. C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease. J Gastroenterol. 2014;49(2):254-262. doi: 10.1007/s00535-013-0807-0.

Roblin X, Marotte H, Leclerc M, Del Tedesco E, Phelip JM, Peyrin-Biroulet L, et al. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. J Crohn’s Colitis. 2015;9(7):525-531. doi: 10.1093/ecco-jcc/jjv061.

Ferreira AI, Lima Capela T, Macedo Silva V, Xavier S, Arieira C, Cúrdia Gonçalves T, et al. P567 How can we predict the development of antibodies to infliximab in Crohn’s disease? J Crohn's Colitis. 2023;17(Supplement 1):i696. doi: 10.1093/ecco-jcc/jjac190.0697.

Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91(4):635-646 doi: 10.1038/clpt.2011.328.

Meuwis MA, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Piver E, et al. Serum calprotectin as a biomarker for Crohn's disease. J Crohns Colitis. 2013;7(12):e678-683 doi: 10.1016/j.crohns.2013.06.008.

Cremer A, Ku J, Amininejad L, Bouvry MR, Brohet F, Liefferinckx C, et al. Variability of faecal calprotectin in inflammatory bowel disease patients: An observational case-control study. J Crohns Colitis. 2019;13(11):1372-9 doi: 10.1093/ecco-jcc/jjz069.

Azramezani Kopi T, Shahrokh S, Mirzaei S, Asadzadeh Aghdaei H, Amini Kadijani A. The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study. Gastroenterol Hepatol Bed Bench. 2019;12(3):183-189. PMID: 31528300.

Guo A, Ross C, Chande N, Gregor J, Ponich T, Khanna R, et al. High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists. Sci Rep. 2022;12(1):1185 doi: 10.1038/s41598-022-05208-9.

Mohamed GA, Mohamed HAE-L, Abo Halima AS, Elshaarawy MEA, Khedr A. Changes in serum oncostatin M levels during treatment of inflammatory bowel disease. Egypt J Hospital Med. 2022;89(2):7217-7125 dooi: 10.21608/ejhm.2022.273068.

Verstockt S, Verstockt B, Machiels K, Vancamelbeke M, Ferrante M, Cleynen I, et al. Oncostatin M is a biomarker of diagnosis, worse disease prognosis, and therapeutic nonresponse in inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(10):1564-1575 doi: 10.1093/ibd/izab032.

Gomes LEM, da Silva FAR, Pascoal LB, Ricci RL, Nogueira G, Camargo MG, et al. Serum levels of infliximab and anti-infliximab antibodies in Brazilian patients with Crohn’s disease. Clinics. 2019;74. doi: 10.6061/clinics/2019/e824.

Reinhold I, Blümel S, Schreiner J, Boyman O, Bögeholz J, Cheetham M, et al. Clinical relevance of anti-TNF antibody trough levels and anti-drug antibodies in treating inflammatory bowel disease patients. Inflamm Intest Dis. 2021;6(1):38-47 doi: 10.1159/000511296.

Downloads

Published

2024-03-24

How to Cite

Saleh, H. H., Khadim , D. J., & Hussein, R. J. (2024). Correlation between Therapeutic Drug Monitoring of Infliximab Serum Trough Levels and other Biomarkers in Iraqi Patients with Crohn’s Disease. Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ), 6(1), 239–245. https://doi.org/10.54133/ajms.v6i1.606

Issue

Section

Original article

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.